Is there a role for plant-made vaccines in the prevention of HIV/AIDS?

Immunology and Cell Biology

Volumn 83, Issue 3, 2005, Pages 239-247

  Webster, Diane E ^a   Thomas, Merlin C ^b   Pickering, Raelene ^a   Whyte, Andrew ^c   Dry, Ian B ^d   Gorry, Paul R ^a   Wesselingh, Steve L ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c UNIVERSITY OF TASMANIA   (Australia)

^d CSIRO   (Australia)

Author keywords

HIV; Oral vaccination; Plant biotechnology; Plant based vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLANT BASED VACCINE; UNCLASSIFIED DRUG; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN DETECTION; CELLULAR IMMUNITY; CLADISTICS; DRUG EFFICACY; EDUCATION PROGRAM; ENDEMIC DISEASE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; QUANTITATIVE DIAGNOSIS; REVIEW; THERMOSTABILITY; VACCINATION; VACCINE PRODUCTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIGENS, VIRAL; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; MICE; PLANTS, GENETICALLY MODIFIED; VACCINES, EDIBLE; VACCINES, SYNTHETIC; VIRAL PROTEINS; VIRAL VACCINES;

EID: 20444421861     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2005.01341.x     Document Type: Review

References (86)

1. World Health Organization (WHO). HIV; Facts and Figures 2003. [Cited 17 February 2005.] Available from: http:// www.who.int/hiv/pub/epidemiology/ imagefile/en/.
2. Atkinson HJ, Green J, Cowgill S, Levesley A. The case for genetically modified crops with a poverty focus. Trends Biotechnol. 2001; 19: 91-6.
3. Schunmann PHD, Coia G, Waterhouse PM. Biopharming the SimpliRED™ HIV diagnostic reagent in barley, potato and tobacco. Mol. Breed. 2002; 9: 113-21.
4. Kumagai M, Turpen T, Weinzettl N et al. Rapid, high-level expression of biologically active alpha-trichosanthin in transfected plants by an RNA viral vector. Proc. Natl Acad. Sci. USA 1993; 90: 427-30.
5. Klausner RD, Fauci AS, Corey L et al. The need for a global HIV vaccine enterprise. Science 2003; 300: 2036-9.
6. Daniell H, Streatfield SJ, Wycoff K. Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants. Trends Plant Sci. 2001; 6: 219-26.
7. Rigano MM, Walmsley AM. Expression systems and developments in plant-made vaccines. Immunol. Cell Biol. 2005; 83: 271-7.
8. Lamphear BJ, Streatfield SJ, Jilka JM et al. Delivery of subunit vaccines in maize seed. J. Control. Release 2002; 85: 169-80.
9. Khandelwal A, Lakshmi Sita G, Shaila MS. Oral immunization of cattle with hemagglutinin protein of rinderpest virus expressed in transgenic peanut induces specific immune responses. Vaccine 2003; 21: 3282-9.
10. Tacket C, Mason H, Losonsky G, Clements J, Levine M, Arntzen C. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat. Med. 1998; 4: 607-609.
11. Kapusta J, Modelska A, Pniewski T et al. Oral immunization of human with transgenic lettuce expressing hepatitis B surface antigen. Adv. Exp. Med. Biol. 2001; 495: 299-303.
12. Tacket C, Mason H, Losonsky G, Estes M, Levine M, Arntzen C. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 2000; 182: 302-305.
13. Yusibov V, Hooper DC, Spitsin SV et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 2002; 20: 3155-64.
14. Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 2004; 22: 4385-9.
15. Thanavala Y, Mahoney M, Pal S et al. Immunogenicity in humans of an edible vaccine for hepatitis B. PNAS 2005; 102: 3378-82.
16. Arakawa T, Chong D, Langridge W. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nat. Biotechnol. 1998; 16: 292-7.
17. Stoger E, Vaquero C, Torres E et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol. Biol. 2000; 42: 583-90.
18. Walmsley AM, Kirk DD, Mason HS. Passive immunization of mice pups through oral immunization of dams with a plant-derived vaccine. Immunol. Lett. 2003; 86: 71-6.
19. Cao H, Kaleebu P, Horn D et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J. Infect. Dis. 2003; 187: 887-95.
20. Yu J, Langridge WH. A plant-based multicomponent vaccine protects mice from enteric diseases. Nat. Biotechnol. 2001; 19: 548-52.
21. Ma J-C, Hikmat B, Wycoff K et al. Characterisation of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nat. Med. 1998; 4: 601-606.
22. Someya K, Cecilia D, Ami Y et al. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. J. Virol. 2005; 79: 1452-62.
23. Gilbert PB, Chiu YL, Allen M et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 2003; 21: 2933-47.
24. Horn ME, Pappu KM, Bailey MR et al. Advantageous features of plant-based systems for the development of HIV vaccines. J. Drug Target. 2003; 11: 539-45.
25. Rowland-Jones SL, Dong T, Fowke KR et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 1998; 102: 1758-65.
26. Mossman SP, Pierce CC, Watson AJ et al. Protective immunity to SIV challenge elicited by vaccination of macaques with multigenic DNA vaccines producing virus-like particles. AIDS Res. Hum. Retroviruses 2004; 20: 425-34.
27. (mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol. 2004; 78: 2212-21.
28. Zhang GG, Rodrigues L, Rovinski B, White KA. Production of HIV-1 p24 protein in transgenic tobacco plants. Mol. Biotechnol. 2002; 20: 131-6.
29. Zhang G, Leung C, Murdin L, Rovinski B, White KA. In planta expression of HIV-1 p24 protein using an RNA plant virus-based expression vector. Mol. Biotechnol. 2000; 14: 99-107.
30. mac Gag p27 capsid protein cholera toxin B subunit fusion protein in transgenic potato. Mol. Biotechnol. 2004; 28: 33-40.
31. mac Gag p27 capsid protein gene expression in potato. Protein Expr. Purif. 2004; 36: 312-17.
32. Brigati C, Giacca M, Noonan DM, Albini A. HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiol. Lett. 2003; 220: 57-65.
33. Fanales-Belasio E, Cafaro A, Cara A et al. HIV-1 Tat-based vaccines: from basic science to clinical trials. DNA Cell Biol. 2002; 21: 599-610.
34. Tikhonov I, Ruckwardt TJ, Hatfield GS, Pauza CD. Tat-neutralizing antibodies in vaccinated macaques. J. Virol. 2003; 77: 3157-66.
35. Caselli E, Betti M, Grossi MP et al. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type tat. J. Immunol. 1999; 162: 5631-8.
36. Zagury JF, Sill A, Blattner W et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 1998; 1: 282-92.
37. Cafaro A, Caputo A, Fracasso C et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 1999; 5: 643-50.
38. Re MC, Vignoli M, Furlini G et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J. Clin. Virol. 2001; 21: 81-9.
39. Kim TG, Langridge WH. Synthesis of an HIV-1 Tat transduction domain-rotavirus enterotoxin fusion protein in transgenic potato. Plant Cell Rep. 2004; 22: 382-7.
40. Martin JL, Sunaryo N, Waldhuber MG, Webster DE, Wesselingh SL. Development of an HIV-1 Tat-based prime boost vaccine strategy. In: Proceedings of the 1st Australian Virology Group Meeting; 5-9 Dec 2001, Fraser Island, Australia. 2001; S11.3.
41. Hammond-Kosack KE, Harrison K, Jones JD. Developmentally regulated cell death on expression of the fungal avirulence gene Avr9 in tomato seedlings carrying the disease-resistance gene Cf-9. Proc. Natl Acad. Sci. USA 1994; 91: 10 445-9.
42. Munro S, Pelham H. A C-terminal signal prevents secretion of luminal ER proteins. Cell 1987; 48: 899-907.
43. Kirsch T, Boehm M, Schuckert O et al. Cloning, high-yield expression in Escherichia coli, and purification of biologically active HIV-1 Tat protein. Protein Expr. Purif. 1996; 8: 75-84.
44. Karasev A, Foulke S, Wellens C et al. Plant based HIV-1 vaccine canditate: Tat protein produced in spinach. Vaccine 2005; 23: 1875-80.
45. Yusibov V, Modelska A, Steplewski K et al. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc. Natl Acad. Sci. USA 1997; 94: 5784-8.
46. Joelson T, Akerblom L, Oxelfelt P, Strandberg B, Tomenius K, Morris TJ. Presentation of a foreign peptide on the surface of tomato bushy stunt virus. J. Gen. Virol. 1997; 78: 1213-17.
47. McInerney TL, Brennan FR, Jones TD, Dimmock NJ. Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide. Vaccine 1999; 17: 1359-68.
48. Marusic C, Rizza P, Lattanzi L et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J. Virol. 2001; 75: 8434-9.
49. Durrani Z, McInerney TL, McLain L et al. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J. Immunol. Methods 1998; 220: 93-103.
50. Porta C, Spall V, Loveland J, Johnson J, Barker P, Lomonossoff G. Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides. Virology 1994; 202: 949-55.
51. Le Buanec H, Vetu C, Lachgar A et al. Induction in mice of anti-Tat mucosal immunity by the intranasal and oral routes. Biomed. Pharmacother. 2001; 55: 316-20.
52. Kaul R, Plummer FA, Kimani J et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 2000; 164: 1602-611.
53. Biasin M, Caputo SL, Speciale L et al. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J. Infect. Dis. 2000; 182: 1365-74.
54. Baig J, Levy DB, McKay PF et al. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J. Virol. 2002; 76: 11 484-90.
55. Barouch DH, Craiu A, Santra S et al. Elicitation of high-frequency cytotoxic T-lymphocyte responses against both dominant and subdominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus monkeys. J. Virol. 2001; 75: 2462-7.
56. Woodland DL. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 2004; 25: 98-104.
57. Newman MJ. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses. Curr. Opin. Investig. Drugs 2002; 3: 374-8.
58. Takeda A, Igarashi H, Nakamura H et al. Protective efficacy of an AIDS vaccine, a single DNA priming followed by a single booster with a recombinant replication-defective Sendai virus vector, in a macaque AIDS model. J. Virol. 2003; 77: 9710-15.
59. Haglund K, Leiner I, Kerksiek K, Buonocore L, Pamer E, Rose JK. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J. Virol 2002; 76: 7506-517.
60. Hel Z, Nacsa J, Tryniszewska E et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and post-challenge CD4+ and CD8+ T cell responses. J. Immunol. 2002; 169: 4778-87.
61. Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl Acad. Sci. USA 2001; 98: 11 539-44.
62. Webster D, Cooney M, Huang Z et al. Successful boosting of a DNA measles immunisation with an oral plant-derived measles vaccine. J. Virol. 2002; 76: 7910-912.
63. Bomsel M, Heyman M, Hocini H et al. Intracellular neutralization of HIV transcytosis across tight epithelial barriers by anti-HIV envelope protein sIgA or IgM. Immunity 1998; 9: 277-87.
64. Moja P, Tranchat C, Tchou I et al. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients. J. Infect. Dis. 2000; 181: 1607-613.
65. Beyrer C, Artenstein AW, Rugpao S et al. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type I highly exposed, persistently seronegative female sex workers in northern Thailand. Chiang Mai HEPS Working Group. J. Infect. Dis. 1999; 179: 59-67.
66. Lehner T, Bergmeier LA, Panagiotidi C et al. Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science 1992; 258: 1365-9.
67. Mestecky J, Jackson S, Moldoveanu Z et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res. Hum. Retroviruses 2004; 20: 972-88.
68. Kim TG, Gruber A, Langridge WH. HIV-1 gp120, V3 cholera toxin B subunit fusion gene expression in transgenic potato. Protein Expr. Purif. 2004; 37: 196-202.
69. Matoba N, Magerus A, Geyer BC et al. A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. Proc. Natl Acad. Sci. USA 2004; 101: 13 584-9.
70. Kim TG, Ruprecht R, Langridge WH. Synthesis and assembly of a cholera toxin B subunit SHIV 89.6p Tat fusion protein in transgenic potato. Protein Expr. Purif. 2004; 35: 313-19.
71. Arakawa T, Yu J, Chong D, Hough J, Engen P, Langridge W. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat. Biotechnol. 1998; 16: 934-8.
72. Streatfield SJ, Howard JA. Plant-based vaccines. Int. J. Parasitol. 2003; 33: 479-93.
73. Sugiyama Y, Hamamoto H, Takemoto S, Watanabe Y, Okada Y. Systemic production of foreign peptides on the particle surface of tobacco mosaic virus. FEBS Lett. 1995; 359: 247-50.
74. Gleba Y, Klimyuk V, Marillonnet S. Magnifection - a new platform for expressing recombinant vaccines in plants. Vaccine 2005; 23: 2042-8.
75. Strobel S, Mowat A. Immune responses to dietary antigens: oral tolerance. Immunol. Today 1999; 19: 173-81.
76. Pecquet S, Leo E, Pritsche R, Pfeifer A, Couvreur P, Fattal E. Oral tolerance elicited in mice by beta-lactoglobulin entrapped in biodegradable microspheres. Vaccine 2000; 18: 1196-202.
77. Bergerot I, Ploix C, Petersen J et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc. Natl Acad. Sci. USA 1997; 94: 4610-614.
78. Blanas E, Carbone F, Allison J, Miller J, Heath W. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996; 274: 1707-709.
79. Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. Biodrugs 2002; 16: 183-200.
80. Tsuji NM, Mizumachi K, Kurisaki J. Interleukin-10-secreting Peyer's patch cells are responsible for active suppression in low-dose oral tolerance. Immunology 2001; 103: 458-64.
81. Castle D, Dalgleish J. Cultivating fertile ground for the introduction of plant-derived vaccines in developing countries. Vaccine 2005; 23: 1881-5.
82. The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 2005; 191: 654-65.
83. Beachy RN, Fitchen JH, Hein MB. Use of plant viruses for delivery of vaccine epitopes. Ann. NY Acad. Sci. 1996; 792: 43-9.
84. McLain L, Porta N, Lomonossoff G, Durrani Z, Dimmock NJ. Human immunodeficiency virus type 1 neutralising antibodies raised to a gp41 peptide expressed on the surface of a plant virus. AIDS Res. Hum. Retroviruses 1995; 11: 327-34.
85. McLain L, Durrani Z, Wisniewski L, Porta C, Lomonossoff G, Dimmock N. Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunised with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus. Vaccine 1996; 14: 799-810.
86. Zhang G. Use of plant virus-based expression systems for the production of HIV vaccines. In: Erickson L, Yu WJ, Brandle J, Rymerson R (eds). Molecular Farming of Plants and Animals for Human and Veterinary Medicine. Netherlands: Kluwer Academic Publishers, 2002: 155-177.